United States· US:0310-9501_35bf673a-53ef-404c-bcdb-08fc92e7e46b

TRUQAP

A capivasertib product containing capivasertib, registered in United States by AstraZeneca Pharmaceuticals LP. The same ATC class is registered in 14 of our 19 countries.

ATC L01EX27

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedTRUQAPATCL01EX27REGISTER NO.US:0310-9501_35bf673a…PACKS LISTED4CHECKEDSeptember 27, 2026

Where it is registered

Capivasertib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EX27 (capivasertib), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 8 of them publish a price we can compare per daily dose

Capivasertib · ATC L01EX27

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of capivasertib costs, country by country.

Normalised to the WHO defined daily dose (0.46 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Capivasertib · price per daily dose (0.46 g)

USD · FX 28 Sept 2026

  • CH Switzerland$320.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
CAPIVASERTIB
Manufacturer
AstraZeneca Pharmaceuticals LP
Country
United States (US)
ATC code
L01EX27
ATC class
Capivasertib
Defined daily dose
0.46 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 4

  • ndc11
    0310-9501-01
  • ndc11
    0310-9501-02
  • ndc11
    0310-9501-04
  • ndc11
    0310-9501-96

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Capivasertib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All capivasertib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Truqap
  • Liechtenstein · Truqap
  • Norway · Truqap

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/262ee317-6cab-448a-aa1e-106adc920b57
GET /v1/drugs/262ee317-6cab-448a-aa1e-106adc920b57?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "200",
  "substance": "CAPIVASERTIB",
  "productndc": "0310-9501",
  "dosage_form": "TABLET, FILM COATED",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA218197",
  "marketing_category": "NDA"
}

See everything about capivasertib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.